Journal Mobile Options
Table of Contents
Vol. 16, No. 5, 2009
Issue release date: June 2009
Neuroimmunomodulation 2009;16:265–271

Regulation of the Hypothalamic-Pituitary-Adrenal Axis

Papadimitriou A. · Priftis K.N.
aThird Department of Pediatrics, University of Athens School of Medicine, Attikon University Hospital, Haidari, Athens, and bDepartment of Allergy-Pneumonology, Penteli Children’s Hospital, Palea Penteli, Greece

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Glucocorticoids (GCs) are essential for the maintenance of homeostasis and enable the organism to prepare for, respond to and manage stress, either physical or emotional. Cortisol, the principal GC in humans, is synthesized in the adrenal cortex. It is released in the circulation in a pulsatile and circadian pattern. GC secretion is governed by hypothalamus and pituitary. The hypothalamus senses changes in the external and internal environment that may disrupt the homeostatic balance of the organism (i.e. stressors), and responds by releasing corticotropin-releasing hormone (CRH) and arginine vasopressin (AVP) from parvocellular neurons projecting from the paraventricular nucleus to the median eminence. These neurohormones are released into the anterior pituitary where they act synergistically via specific receptors (CRH-R1 and V1B receptor, respectively) to trigger the release of the adrenocorticotropic hormone (ACTH) from the corticotrope cells into the systemic circulation. In turn, ACTH exerts its actions on the adrenal cortex via specific receptors, type 2 melanocortin receptors (MC2-R), to initiate the synthesis of cortisol, which is released immediately into the systemic circulation by diffusion. Hypothalamic CRH and AVP, pituitary ACTH and adrenal GCs comprise the hypothalamic-pituitary-adrenal (HPA) axis. In this brief review, the HPA axis and the various factors that regulate its function are described.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Miller WL: StAR search – what we know about how the steroidogenic acute regulatory protein mediates mitochondrial cholesterol import. Mol Endocrinol 2007;21:589–601.
  2. Payne AH, Hales DB: Overview of steroidogenic enzymes in the pathway from cholesterol to active steroid hormones. Endocr Rev 2004;25:947–970.
  3. Habib KE, Gold PW, Chrousos GP: Neuroendocrinology of stress. Endocrinol Metab Clin North Am 2001;30:695–728.
  4. Selye H: A syndrome produced by diverse nocuous agents. Nature 1936;138:32–36.

    External Resources

  5. McEwen BS: Physiology and neurobiology of stress and adaptation: central role of the brain. Physiol Rev 2007;87:873–904.
  6. Chrousos GP, Gold PW: The concepts of stress system disorders. Overview of physical and behavioral homeostasis. JAMA 1992;267:1244–1252.
  7. Munck A, Guyre PM, Holbrook NJ: Physiological functions of glucocorticoids in stress and their relation to pharmacological actions. Endocr Rev 1984;5:25–44.
  8. Munck A, Náray-Fejes-Tóth A: The ups and downs of glucocorticoid physiology. Permissive and suppressive effects revisited. Mol Cell Endocrinol 1992;90:C1–C4.
  9. Chrousos GP: The stress response and immune function: clinical implications. The 1999 Novera H. Spector Lecture. Ann NY Acad Sci 2000;917:38–67.
  10. Fuller RW: The involvement of serotonin in regulation of pituitary-adrenocortical function. Front Neuroendocrinol 1992;13:250–270.
  11. Calogero AE, Gallucci WT, Chrousos GP, Gold PW: Interaction between GABAergic neurotransmission and rat hypothalamic CRH in vitro. Brain Res 1988;463:28–36.
  12. Chrousos GP: The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. N Engl J Med 2004;332:1351–1362.
  13. Vale W, Spiess J, Rivier C, Rivier J: Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and β-endorphin. Science 1981;213:1394–1397.
  14. Majzoub JA: Corticotropin-releasing hormone physiology. Eur J Endocrinol 2006;155(suppl 1):71–76.

    External Resources

  15. Borrelli E: A chilled-out knockout. Nat Genet 1998;19:108–109.
  16. Chen R, Lewis KA, Perrin MH, Vale WW: Expression cloning of a human corticotropin-releasing-factor receptor. Proc Natl Acad Sci USA 1993;90:8967–8971.
  17. Lovenberg TW, Liaw CW, Grigoriadis DE, Clevenger W, Chalmers DT, De Souza EB, Oltersdorf T: Cloning and characterization of a functionally distinct corticotropin-releasing factor receptor subtype from rat brain. Proc Natl Acad Sci USA 1995;92:836–840.
  18. Hillhouse EW, Grammatopoulos DK: The molecular mechanisms underlying the regulation of the biological activity of corticotropin-releasing hormone receptors: implications for physiology and pathophysiology. Endocr Rev 2006;27:260–286.
  19. Kostich WA, Chen A, Sperle K, Largent BL: Molecular identification and analysis of a novel human corticotropin-releasing factor (CRF) receptor: the CRF2γ receptor. Mol Endocrinol 1998;12:1077–1085.
  20. Martinez V, Wang L, Million M, Rivier J, Tache Y: Urocortins and the regulation of gastrointestinal motor function and visceral pain. Peptides 2004;25:1733–1744.
  21. Li C, Vaughan J, Sawchenko PE, Vale WW: Urocortin III-immunoreactive projections in rat brain: partial overlap with sites of type 2 corticotrophin-releasing factor receptor expression. J Neurosci 2002;22:991–1001.
  22. Kuperman Y, Chen A: Urocortins: emerging metabolic and energy homeostasis perspectives. Trends Endocrinol Metab 2008;19:122–129.
  23. Suda T, Kageyama K, Sakihara S, Nigawara T: Physiological roles of urocortins, human homologues of fish urotensin I, and their receptors. Peptides 2004;25:1689–1701.
  24. Woods RJ, Grossman A, Saphier P, Kennedy K, Ur E, Behan D, Potter E, Vale W, Lowry PJ: Association of human corticotropin-releasing hormone to its binding protein in blood may trigger clearance of the complex. J Clin Endocrinol Metab 1994;78:73–76.
  25. Lamolet B, Pulichino AM, Lamonerie T, Gauthier Y, Brue T, Enjalbert A, Drouin J: A pituitary cell-restricted T box factor, Tpit, activates POMC transcription in cooperation with Pitx homeoproteins. Cell 2001;104:849–859.
  26. Lamberts SW, Verleun T, Oosterom R, de Jong F, Hackeng WH: Corticotropin-releasing factor (ovine) and vasopressin exert a synergistic effect on adrenocorticotropin release in man. J Clin Endocrinol Metab 1984;58:298–303.
  27. Legros JJ, Chiodera P, Demey-Ponsart E: Inhibitory influence of exogenous oxytocin on adrenocorticotropin secretion in normal human subjects. J Clin Endocrinol Metab 1982;55:1035–1039.
  28. Taylor T, Dluhy RG, Williams GH: β-Endorphin suppresses adrenocorticotropin and cortisol levels in normal human subjects. J Clin Endocrinol Metab 1983;57:592–596.
  29. Cota D, Steiner MA, Marsicano G, Cervino C, Herman JP, Grübler Y, Stalla J, Pasquali R, Lutz B, Stalla GK, Pagotto U: Requirement of cannabinoid receptor type 1 for the basal modulation of hypothalamic-pituitary-adrenal axis function. Endocrinology 2007;148:1574–1581.
  30. Alexander LD, Evans K, Sander LD: A possible involvement of VIP in feeding-induced secretion of ACTH and corticosterone in the rat. Physiol Behav 1995;58:409–413.
  31. Alexander LD, Sander LD: Involvement of vasopressin and corticotropin-releasing hormone in VIP- and PHI-induced secretion of ACTH and corticosterone. Neuropeptides 1995;28:167–173.
  32. Al-Damluji S, Francis D: Activation of central α1-adrenoceptors in humans stimulates secretion of prolactin and TSH, as well as ACTH. Am J Physiol 1993;264:E208–E214.
  33. Korbonits M, Kaltsas G, Perry LA, Grossman AB, Monson JP, Besser GM, Trainer PJ: Hexarelin as a test of pituitary reserve in patients with pituitary disease. Clin Endocrinol (Oxf) 1999;51:369–375.
  34. Korbonits M, Kaltsas G, Perry LA, Putignano P, Grossman AB, Besser GM, Trainer PJ: The growth hormone secretagogue hexarelin stimulates the hypothalamo-pituitary-adrenal axis via arginine vasopressin. J Clin Endocrinol Metab 1999;84:2489–2495.
  35. Spinazzi R, Andreis PG, Rossi GP, Nussdorfer GG: Orexins in the regulation of the hypothalamic-pituitary-adrenal axis. Pharmacol Rev 2006;58:46–57.
  36. Besedovsky HO, del Rey A: Immune-neuroendocrine interactions: facts and hypotheses. Endocr Rev 1996;17:64–102.
  37. Ray DW, Ren SG, Melmed S: Leukemia inhibitory factor stimulates proopiomelanocortin expression in a corticotroph cell line. Role of STAT pathway. J Clin Invest 1996;97:1852–1859.
  38. Young EA, Carlson NE, Brown MB: 24-Hour ACTH and cortisol pulsatility in depressed women. Neuropsychopharmacology 2001;25:267–276.
  39. Getting SJ: Targeting melanocortin receptors as potential novel therapeutics. Pharmacol Ther 2006;111:1–15.
  40. Enyeart JJ, Mlinar B, Enyeart JA: T-type Ca2+ channels are required for adrenocorticotropin-stimulated cortisol production by bovine adrenal zona fasciculata cells. Mol Endocrinol 1993;7:1031–1040.
  41. Munari-Silem Y, Lebrethon MC, Morand I, Rousset B, Saez JM: Gap junction-mediated cell-to-cell communication in bovine and human adrenal cells. A process whereby cells increase their responsiveness to physiological corticotropin concentrations. J Clin Invest 1995;95:1429–1439.
  42. Bose HS, Sugawara T, Strauss JF 3rd, Miller WL: The pathophysiology and genetics of congenital lipoid adrenal hyperplasia. International Congenital Lipoid Adrenal Hyperplasia Consortium. N Engl J Med 1996;335:1870–1878.
  43. Blondet A, Doghman M, Penhoat A, Durand P, Bégeot M, Naville D: The human MC2-R gene expression: different aspects of its control. Endocr Res 2002;28:275–280.
  44. Oakley RH, Jewell CM, Yudt MR, Bofetiado DM, Cidlowski JA: The dominant negative activity of the human glucocorticoid receptor β-isoform. Specificity and mechanisms of action. J Biol Chem 1999;274:27857–27866.
  45. Chrousos GP, Kino T: Glucocorticoid action networks and complex psychiatric and/or somatic disorders. Stress 2007;10:213–219.
  46. Buckingham JC: Glucocorticoids: exemplars of multi-tasking. Br J Pharmacol 2006;147(suppl 1):S258–S268.
  47. Keller-Wood ME, Dallman MF: Corticosteroid inhibition of ACTH secretion. Endocr Rev 1984;5:1–24.
  48. Tasker JG, Di S, Malcher-Lopes R: Rapid glucocorticoid signaling via membrane-associated receptors. Endocrinology 2006;147:5549–5556.
  49. Di S, Malcher-Lopes R, Marcheselli VL, Bazan NG, Tasker JG: Rapid glucocorticoid-mediated endocannabinoid release and opposing regulation of glutamate and γ-aminobutyric acid inputs to hypothalamic magnocellular neurons. Endocrinology 2005;146:4292–4301.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50